|
|
Post by markado on Jul 19, 2019 11:25:06 GMT -5
Record week(s) on scripts
Approval for distribution in a measurable foreign market
Elimination of debt
Buy back of warrants/shares probably as part of the above,
Pipeline partnerships
Drug delivery system validation
AND, our stock price hovers at less than 5 cents above it's historic low, pre RS.
Effing amazing.
Where our board and leadership appear to be failing us is in convincing the marketplace and other strategic stakeholders that MNKD is worth well more than just Afrezza, even though it remains to be on linear track to have us B/E by next June, without breakout events.
I'm not going anywhere, but our executives need lessons on market optics and narrative control for value creation and validation. This is just embarassing.
|
|
|
|
Post by buyitonsale on Jul 19, 2019 11:35:19 GMT -5
Short sellers are stronger financially than the company or any of its supporters.
What leadership needs is to find a way to eliminate the float or at least reduce it below the current short interest levels.
Know anybody who has $100MM and wants to make 1B ?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 19, 2019 11:43:04 GMT -5
Record week(s) on scripts Approval for distribution in a measurable foreign market Elimination of debt Buy back of warrants/shares probably as part of the above, Pipeline partnerships Drug delivery system validation AND, our stock price hovers at less than 5 cents above it's historic low, pre RS. Effing amazing. Where our board and leadership appear to be failing us is in convincing the marketplace and other strategic stakeholders that MNKD is worth well more than just Afrezza, even though it remains to be on linear track to have us B/E by next June, without breakout events. I'm not going anywhere, but our executives need lessons on market optics and narrative control for value creation and validation. This is just embarassing. You do realize it's because of the Deerfield Deal. MGMT has been working on Auxiliary Power waiting for the MAIN POWER to come back on and that will happen when Deerfield is out of their lives. Now DF could be in on the new RECAP deal but this time MNKD gets to dictate the terms. |
|
|
|
Post by novafett on Jul 19, 2019 11:45:13 GMT -5
How much are we now on the hook for with Deerfield? I don't have time to follow it close enough but have the sense that we're getting close to paying them off? Am I mistaken?
|
|
|
|
Post by traderdennis on Jul 19, 2019 11:48:33 GMT -5
How much are we now on the hook for with Deerfield? I don't have time to follow it close enough but have the sense that we're getting close to paying them off? Am I mistaken? If I remember correctly, on the hook for 5MM in loan payments which is in escrow and about 75MM in milestone payments. 5 MM of the milestone will come due by end of 2h 2019. |
|
|
|
Post by traderdennis on Jul 19, 2019 11:49:51 GMT -5
Record week(s) on scripts Approval for distribution in a measurable foreign market Elimination of debt Buy back of warrants/shares probably as part of the above, Pipeline partnerships Drug delivery system validation AND, our stock price hovers at less than 5 cents above it's historic low, pre RS. Effing amazing. Where our board and leadership appear to be failing us is in convincing the marketplace and other strategic stakeholders that MNKD is worth well more than just Afrezza, even though it remains to be on linear track to have us B/E by next June, without breakout events. I'm not going anywhere, but our executives need lessons on market optics and narrative control for value creation and validation. This is just embarassing. 1.1MM in retail revenue is less than 25% needed to cover cash costs for the company. That is why the stock price will continue to decline in anticipation for the next round of dilution. |
|
|
|
Post by ktim on Jul 19, 2019 11:49:57 GMT -5
Record week(s) on scripts Approval for distribution in a measurable foreign market Elimination of debt Buy back of warrants/shares probably as part of the above, Pipeline partnerships Drug delivery system validation AND, our stock price hovers at less than 5 cents above it's historic low, pre RS. Effing amazing. Where our board and leadership appear to be failing us is in convincing the marketplace and other strategic stakeholders that MNKD is worth well more than just Afrezza, even though it remains to be on linear track to have us B/E by next June, without breakout events. I'm not going anywhere, but our executives need lessons on market optics and narrative control for value creation and validation. This is just embarassing. If you mean break even from Afrezza sales, you are way off. It would be years out if the current growth is modeled as linear and extrapolated. That gets at the crux of current share price. We need to convincingly break out of linear growth and then you'll see the share price move. Today's numbers are encouraging, but one week is not a pattern. |
|
|
|
Post by novafett on Jul 19, 2019 11:59:47 GMT -5
How much are we now on the hook for with Deerfield? I don't have time to follow it close enough but have the sense that we're getting close to paying them off? Am I mistaken? If I remember correctly, on the hook for 5MM in loan payments which is in escrow and about 75MM in milestone payments. 5 MM of the milestone will come due by end of 2h 2019. Ok so much more than I thought. Thanks for the clarification. |
|
|
|
Post by matt on Jul 19, 2019 13:17:10 GMT -5
If I remember correctly, on the hook for 5MM in loan payments which is in escrow and about 75MM in milestone payments. 5 MM of the milestone will come due by end of 2h 2019. Ok so much more than I thought. Thanks for the clarification. The remaining milestone payments are tied to cumulative sales of Afrezza and if the company has to pay out the full amount the shareholders will be dancing in the street. Blowing through milestone targets is a good thing! However, don't forget that Deerfield gets so much discussion only because they are the senior lender and are in a position to make life difficult for MNKD. Once the DF debt portion is paid off, there is another $91 million in debt and there will be new senior lenders; the company is a very long way from being debt free. It is a bit like paying off a second mortgage on your house; that is an accomplishment but you still have the first mortgage to worry about. As of the last 10-Q, the liabilities exceeded the value of assets by $188 million. |
|
|
|
Post by agedhippie on Jul 19, 2019 13:35:58 GMT -5
You do realize it's because of the Deerfield Deal. MGMT has been working on Auxiliary Power waiting for the MAIN POWER to come back on and that will happen when Deerfield is out of their lives. Now DF could be in on the new RECAP deal but this time MNKD gets to dictate the terms. I think you are being wildly optimistic if you think MNKD can dictate terms! If there is another deal with Deerfield expect more of the same at around a 9.5% rate. Deerfield likes the micro-caps because they are a captive market. These are companies that don't have the option of using the bond market so they are stuck with the lenders and the lenders know it. |
|
|
|
Post by agedhippie on Jul 19, 2019 14:09:41 GMT -5
If you mean break even from Afrezza sales, you are way off. It would be years out if the current growth is modeled as linear and extrapolated. That gets at the crux of current share price. We need to convincingly break out of linear growth and then you'll see the share price move. Today's numbers are encouraging, but one week is not a pattern. Profit from Afrezza last quarter were $1.1M on $8.2M sales. S&GA cost $27.0M. That is why the shorts are around. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 19, 2019 19:35:28 GMT -5
You do realize it's because of the Deerfield Deal. MGMT has been working on Auxiliary Power waiting for the MAIN POWER to come back on and that will happen when Deerfield is out of their lives. Now DF could be in on the new RECAP deal but this time MNKD gets to dictate the terms. I think you are being wildly optimistic if you think MNKD can dictate terms! If there is another deal with Deerfield expect more of the same at around a 9.5% rate. Deerfield likes the micro-caps because they are a captive market. These are companies that don't have the option of using the bond market so they are stuck with the lenders and the lenders know it. MNKD can and will dictate terms. MNKD will shop their deal and will narrow it down to the top 3 and then tell them to sharpen their pencils and make a new proposal. MNKD is in a much better shape than 6 years ago. And the rate of 9.25% is very high. They will command a 5-6% rate with NO TOXIC TERMS. If SENS can do a new deal yesterday at 5.25% then MNKD should do much better. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 19, 2019 19:41:59 GMT -5
If you mean break even from Afrezza sales, you are way off. It would be years out if the current growth is modeled as linear and extrapolated. That gets at the crux of current share price. We need to convincingly break out of linear growth and then you'll see the share price move. Today's numbers are encouraging, but one week is not a pattern. Profit from Afrezza last quarter were $1.1M on $8.2M sales. S&GA cost $27.0M. That is why the shorts are around. SHORTS are around because they knew the terms of the DEERFIELD DEAL from DAY ONE and knew MNKD would be hamstrung with their operations. Let's see if they are around after MNKD gets Deerfield paid off and RECAPS the company. All MNKD need is for UTHR to sign on to the 2nd molecule, a new marketing partner and hopefully a new R&D partner for their most advanced pipeline molecules. |
|
|
|
Post by rtmd on Jul 19, 2019 22:07:16 GMT -5
I think you are being wildly optimistic if you think MNKD can dictate terms! If there is another deal with Deerfield expect more of the same at around a 9.5% rate. Deerfield likes the micro-caps because they are a captive market. These are companies that don't have the option of using the bond market so they are stuck with the lenders and the lenders know it. MNKD can and will dictate terms. MNKD will shop their deal and will narrow it down to the top 3 and then tell them to sharpen their pencils and make a new proposal. MNKD is in a much better shape than 6 years ago. And the rate of 9.25% is very high. They will command a 5-6% rate with NO TOXIC TERMS. If SENS can do a new deal yesterday at 5.25% then MNKD should do much better. SENS had around a 100 million cash, about 40 million debt , and Roche as a partner. I don't believe Mannkind's situation is quite analogous. |
|
|
|
Post by traderdennis on Jul 19, 2019 22:48:55 GMT -5
MNKD can and will dictate terms. MNKD will shop their deal and will narrow it down to the top 3 and then tell them to sharpen their pencils and make a new proposal. MNKD is in a much better shape than 6 years ago. And the rate of 9.25% is very high. They will command a 5-6% rate with NO TOXIC TERMS. If SENS can do a new deal yesterday at 5.25% then MNKD should do much better. SENS had around a 100 million cash, about 40 million debt , and Roche as a partner. I don't believe Mannkind's situation is quite analogous. I am also guessing SENS product has not been on the market for five years. Also their product is not selling way below expectations and has a large percentage of doctors who want no business with Afrezza. |
|
